Philadelphia College of Osteopathic Medicine

DigitalCommons@PCOM
PCOM Biomedical Studies Student Scholarship

Student Dissertations, Theses and Papers

2021

Allicin stimulates the phosphorylation of eNOSSer1177 via a PI3Kdependent mechanism in type-I diabetic donor coronary artery
endothelial cells
Hunter Alberto Vásquez
Philadelphia College of Osteopathic Medicine

Follow this and additional works at: https://digitalcommons.pcom.edu/biomed
Part of the Medicine and Health Sciences Commons

Recommended Citation
Vásquez, Hunter Alberto, "Allicin stimulates the phosphorylation of eNOSSer1177 via a PI3K-dependent
mechanism in type-I diabetic donor coronary artery endothelial cells" (2021). PCOM Biomedical Studies
Student Scholarship. 206.
https://digitalcommons.pcom.edu/biomed/206

This Thesis is brought to you for free and open access by the Student Dissertations, Theses and Papers at
DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Biomedical Studies Student Scholarship by
an authorized administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.

i

Philadelphia College of Osteopathic Medicine
Graduate Program in Biomedical Sciences
Department of Bio-Medical Sciences

Allicin stimulates the phosphorylation of eNOSSer1177 via a PI3K-dependent mechanism in
type-I diabetic donor coronary artery endothelial cells

A Thesis in Biomedical Sciences by Hunter Alberto Vásquez
Copyright 2021 Hunter Alberto Vásquez

Submitted in Partial Fulfillment of the Requirements for the Degree of Masters in Biomedical
Sciences
June 2021

This thesis has been presented to and accepted by the Associate Dean for Curriculum and
Research Office of Philadelphia College of Osteopathic Medicine in partial fulfillment of
the requirements for the degree of Master of Science in Biomedical Sciences.
We, the undersigned, duly appointed committee have read and examined this manuscript
and certify it is adequate in scope and quality as a thesis for this master’s degree. We
approve the content of the thesis to be submitted for processing and acceptance.

iii

ABSTRACT
INTRODUCTION: The World Health Organization (WHO) indicates that deaths from noncommunicable diseases (NCDs) are projected to increase to approximately 52 million by the year
2030. Of these NCDs, cardiovascular diseases (CVDs) constitute the number one cause of death
globally and are the major source of morbidity and mortality associated with diabetes mellitus
(DM). CVD manifests early in individuals with DM by way of vascular dysfunction,
characterized by depressed nitric oxide (NO) production. As such, interventions to mediate the
comorbidities associated with DM are being investigated.
OBJECTIVES: The primary objective of this study was to investigate the mechanism of action
for allicin, a naturally-occurring compound in dietary garlic, to increase nitric oxide (NO)
production in type-I diabetic donor coronary artery endothelial cells (DHCAEC-I).
METHODS: Endogenous H2S production following healthy donor coronary artery endothelial
cell (HCAEC) and DHCAEC-I treatment with allicin was measured by way of fluorescence
microscopy using the cell-trappable fluorogenic probe SF7-AM. Similarly, DAF-FM DA was
used to measure NO production in the presence of allicin with and without wortmannin, an
inhibitor targeting PI3K. To confirm the findings of DAF-FM DA fluorescence microscopy,
immunoblots targeting p-eNOSSer1177, eNOS, p-AktSer473, and Akt were employed.
RESULTS: Treatment of HCAEC and DHCAEC-I with allicin resulted in increases in H2S by
126% and 85%, respectively (p < 0.01). NO production following allicin treatment increased in
DHCAEC-I by 66% (p < 0.0001), the effect of which was diminished by the use of wortmannin
(p < 0.0001). eNOSSer1177 phosphorylation in DHCAEC-I increased 89% from baseline after
treatment with allicin (p < 0.05), the effect of which was also reversed by the use of wortmannin
(p < 0.01). Allicin had no statistically-significant effects on NO production or eNOSSer1177
phosphorylation in HCAEC, and had no statistically-significant effects on AktSer473
phosphorylation in HCAEC or DHCAEC-I.
CONCLUSION: These data strongly support the hypothesis that allicin-mediated NO
production is dependent on PI3K in DHCAEC-I. Future experiments are needed to determine the
specific involvement of H2S and the targeted proteins downstream of PI3K.
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INTRODUCTION

1.1 Cardiovascular Disease
The World Health Organization (WHO) indicates that deaths from noncommunicable diseases
(NCDs) are projected to increase to approximately 52 million by the year 2030 (Chestnov, 2014).
Of these NCDs, cardiovascular diseases (CVDs) constitute the number one cause of death
globally and represent a host of heart and vascular diseases, including coronary artery disease
(CAD, i.e., heart attack), cerebrovascular disease (i.e., stroke), and diseases of the aorta and
arteries such as hypertension, among others (Mendis et al., 2014). CVDs are generally caused by
risk factors that are divided into two categories: modifiable and non-modifiable. Of those in the
latter, the most common are age, gender, and family history (Balakumar et al., 2016).
Hypertension, tobacco use, physical inactivity, unhealthy diet, and diabetes mellitus (DM)
constitute the most common of the risk factors that are categorized as modifiable (Balakumar et
al., 2016).

1.1.1 Coronary Artery Disease
The hallmark of CAD is the impediment of blood flow through the vessel lumen of the coronary
arteries resulting from the development of atherosclerotic plaques (APs) (Shahjehan and Bhutta,
2021). APs generally develop from an initial vascular insult to the tunica intima followed by
recruitment of circulating monocytes (Shahjehan and Bhutta, 2021), which attach and migrate
through interendothelial junctions in the tunica intima via interactions with PECAM (CD31)
junctional adhesion molecules (Scott, 2004) where they become macrophages in the
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subendothelial space. Any one or more of three events may then trigger the formation of foam
cells from the subendothelial macrophages: 1) uptake of oxidized low-density lipoprotein (oxLDL) through expression of scavenger receptors CD36 and SR-A (Scott, 2004); 2) excessive
cholesterol esterification; and/or 3) impaired cholesterol release (Yu et al., 2013). While these
subendothelial accumulations of cholesterol-laden foam cells (or “fatty streaks”) are not
necessarily clinically-significant, they serve as precursors for more advanced lesions
characterized by a necrotic core surrounded by smooth muscle and extracellular matrix (Lusis,
2000) that may become calcified over time (Shahjehan and Bhutta, 2021). Consequently, such
lesions are common risk factors for ruptures that may lead to partial or total occlusion of the
coronary lumen, thus resulting in acute coronary syndromes (Shahjehan and Bhutta, 2021).

This occlusion of the coronary artery lumen, leading to the cessation of blood flow, typically
results in acute myocardial infarction (MI), particularly if the cessation ranges in time between 20
and 40 minutes (Ojha and Dahmoon, 2020). In cases of coronary occlusion, what follows is lack
of oxygenation of the myocardium, resulting in disruption of the sarcolemma and myofibril
relaxation (Ojha and Dhamoon, 2020). With sustained cessation follows necrosis of the
myocardium from the sub-endocardium to the sub-epicardium, and depending on the extent to
which the necrosis has spread, could compromise normal cardiac function (Ojha and Dhamoon,
2020). Such necrotic myocardial tissue is ultimately replaced by collagenous tissue that, in quite
the majority of cases, interferes with the mechanical properties of healthy myocardial tissue, such
as increasing the resistance of circumferential stretch (Holmes et al., 1997), further compounding
the risk factors of CVD.
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1.1.2 Hypertension
Of the most notable risk factors for the morbidity and mortality associated with CVD is systemic
arterial hypertension (SAH) (Oparil et al., 2018), which can be defined as persistently elevated
arterial blood pressure (BP), typically exceeding systolic values of 130 mmHg and diastolic
values of 80 mmHg (Iqbal and Jamal, 2020). While the pathophysiology of SAH is complex and
at times multifactorial, genetic predisposition with the addition of environmental factors increases
the probability SAH development (Oparil et al., 2018).

Of these environmental factors, sodium (Na+) plays a crucial role, particularly due to its
involvement in blood volume regulation. Increases in dietary Na+ in normotensive individuals is
typically followed by water retention and/or hemodynamic changes as compensatory mechanisms
to maintain stable BP levels (Oparil et al., 2018); however, in addition to high water retention,
sustained increases in Na+ intake may result in increased systemic peripheral resistance,
endothelial dysfunction, and changes to the structure of the large arteries (Grillo et al., 2019). For
example, high Na+ intake stimulates the retention of water through an osmolarity gradient,
resulting in an increase in blood volume, which consequently increases cardiac output (CO)
(Blaustein et al., 2012). As a result of the increased CO and its contribution to tissue
overperfusion, total peripheral resistance (TPR) increases, thus sustaining the elevated BP
(Blaustein et al., 2012).
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While increased Na+ intake is certainly a risk factor for SAH, it should be noted that the intake of
Na+ is not the sole contributor. In fact, dysfunctions or inappropriate activation of the reninangiotensin-aldosterone system (RAAS) is key as well, which is a significant regulator of blood
volume and vascular resistance on a prolonged basis (Fountain and Lappin, 2020). Under normal
conditions, prorenin is both released by and cleaved by juxtaglomerular (JC) cells to form renin in
response to decreased renal blood pressure, decreased sodium loads in the distal convoluted
tubule (DCT), or beta-activation (Fountain and Lappin, 2020). Following cleavage, renin can act
on the liver-produced angiotensinogen, cleaving it to angiotensin I (ATI). Lastly, the inactive ATI
can be converted to the active angiotensin II (ATII) by angiotensin converting enzyme (ACE) in
the vascular endothelium of the lungs and kidneys (Fountain and Lappin, 2020). ATII can
subsequently bind AT receptors I and II in the kidney, adrenal cortex, arterioles, and brain, and
while the full scope of AT receptor functions are still being investigated, studies have shown
increases in nitric oxide (NO) production as a result (Fountain and Lappin, 2020). In addition,
ATII is responsible for increasing Na+ reabsorption directly through the Na-H exchanger in the
proximal convoluted tubule (PCT), or the insertion of luminal Na+ channels and basolateral
Na+/K+ ATPase proteins in the DCT by way of aldosterone stimulation in the adrenal cortex
(Fountain and Lappin, 2020). In all, these mechanisms are targeted to increasing Na+
reabsorption.

While these mechanisms are well-suited for managing blood volume on a prolonged basis,
inappropriate activation of the RAAS can lead to the development of hypertension (Fountain and
Lappin, 2020). For example, JC cells are prone to sense a decreased blood volume subsequent to a
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renal artery stenosis, and thereby activate the RAAS, resulting in increased blood volume
circulation (Fountain and Lappin, 2020).

1.2 Diabetes Mellitus
DM is a disease in which the β cells of the pancreas are unable to sufficiently produce insulin
due to autoimmune dysfunction (type I, T1DM) or when cellular responses to insulin are
resistant (type II, T2DM) (Inzucchi et al., 2010). DM continues to be a growing epidemic in the
United States with a current prevalence of more than 10% of the population (CDC, 2020) and
projections that such will rise an additional 200 million by the year 2040 (Goyal and Ishwarlal,
2020). Of the myriad of secondary complications, vascular dysfunction has been observed in a
large subset of these patients in a condition that has been termed diabetic vascular disease
(DVD).

1.2.1 Insulin
Insulin is an anabolic peptide hormone produced by the β cells of the islets of Langerhans in the
pancreas. Structurally, insulin is a single-chain polypeptide consisting of both proinsulin and a
signal peptide, the former being released after translocation into the endoplasmic reticulum
(Vargas et al., 2021). After release, proinsulin’s A and B chains, which are joined continuously
through a C domain, are cleaved to release insulin (A and B chains linked via a disulfide bond)
independently along with C-peptide (Vargas et al., 2021).
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The soluble insulin peptide hormone exerts its effects through binding of insulin receptors
(INSRs) on target cells such as those in skeletal muscle, adipose tissue, and the liver (Petersen
and Shulman, 2018). INSRs comprise an α2β2 heterotetramer consisting of two α-subunits and
two β-subunits, the former of which are extracellular and the latter being transcellular and
containing cytoplasmic tyrosine kinase domains (Hubbard et al., 2013). While there are two
isoforms of INSRs, A and B, the B isoform is more metabolically relevant in adults with a high
specificity in the skeletal muscle, adipose tissue, and particularly in hepatic cells (Petersen and
Shulman, 2018).

Functionally, insulin stimulates the uptake of glucose via transmembrane glucose transporter
(GLUT) proteins, predominantly via GLUT4 in the skeletal muscle and adipose tissue and
GLUT2 in the liver (Vargas et al., 2020). Insulin-mediated glucose uptake regulated by GLUT4,
for example, follows that insulin begins by binding to the α-subunit of an INSR, stimulating the
phosphorylation of one β subunit on specific tyrosine residues within INSR’s activation loop as
well as autophosphorylation of other tyrosine residues within the intracellular tail (Chang et al.,
2004). This INSR activation subsequently mediates the phosphorylation of insulin receptor
substrates (IRS) 1-4 (Chang et al., 2004), which bind and activate phosphatidylinositol 3-kinase
(PI3K), in turn activating Akt (note: the PI3K/Akt pathway is described in detail in section 1.5).
Upon activation of Akt, intracellular GLUT4-rich vesicles translocate to the cell membrane,
inserting GLUT4 transcellularly and facilitating the uptake of glucose (Wang et al., 2020).
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1.2.2 Type I Diabetes Mellitus
T1DM is a chronic autoimmune disease resulting in the destruction of the β-cells in the
pancreatic islets, subsequently resulting in the secondary decrease in the production of insulin
(Lucier and Weinstock, 2021), an anabolic peptide hormone responsible for the regulation of
glucose uptake in the peripheral tissues and metabolism of carbohydrates, lipids, and proteins
(Wilcox, 2005). While the precise etiology of T1DM is multifaceted, and much remains elusive,
the disease is a well-studied heritable polygenic disease with approximately 50% of the
prevalence being linked to two human leukocyte antigen (HLA) major histocompatibility
complex II (MHC class II) haplotypes: HLA-DR3-DQ2 and HLA-DR4-Q8 (DiMeglio et al.
2018). While diagnosis of T1DM through HLA risk or familial risk have increased, non-HLA
loci have been associated with risk for T1DM as well, yielding early diagnoses problematic, as
non-HLA loci alone cannot be used to predict the development of T1DM (DiMeglio et al. 2018).

While genetic predispositions account for approximately half of the cases of T1DM (DiMeglio et
al. 2018), a number of environmental factors may also play an important role in the pathogenesis.
Originally described by epidemiological observations, exposure to viruses (i.e., rubella or
enteroviruses) or toxins and nutrients (cow’s milk and cereals) may contribute to the generation
of pancreatic autoantibodies, though the specific effects of these factors remain unclear (Paschou
et al., 2017).
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The onset of T1DM typically begins in stage 1 of 3, characterized by normal fasting glucose and
glucose tolerance, with ≥2 pancreatic autoantibodies (Lucier and Weinstock, 2021). The
progression to stage 2 is marked by ≥2 pancreatic autoantibodies with the addition of
dysglycemia (impaired fasting glucose or glucose tolerance, or hemoglobin A1c between 5.76.4%), followed by stage 3 being characterized by hyperglycemia (Lucier and Weinstock, 2021).

1.2.3 Type II Diabetes Mellitus
While T1DM is a cell-mediated autoimmune dysfunction of pancreatic β-cells, T2DM is
associated with β-cell dysfunction (Goyal and Ishwarlal, 2020), insulin resistance in the
peripheral tissues (Freeman and Pennings, 2020), or both, and accounts for the majority of all
cases of DM (Goyal and Ishwarlal, 2020). Of the peripheral tissues, the three primary sites of
insulin resistance are the muscle tissue, adipose tissue, and the liver (Freeman and Pennings,
2020), typically beginning in the muscle (Zhang et al., 2019) as it accounts for 70% of glucose
uptake (Freeman and Pennings, 2020), thus having a large effect on the turnover of glucose
(DeFronzo and Tripathy, 2009).

The mechanisms of action for insulin resistance in skeletal muscle are complex, however a
number of studies, first being suggested by Randle et al. (1963), have proposed an association
between INSR sensitivity and saturated fatty acids. This study in particular, termed the “Randle
Cycle”, proposes that increased fatty acid (β) oxidation increases the production of acetyl CoA,
increasing both the levels of citrate and the ratio of ATP/ADP, and consequently the inhibition of
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phosphofructokinase (PFK), accumulation of glucose 6-phosphate, and inhibition of hexokinase,
finally resulting in increased intracellular glucose and thus reduced glucose uptake (Martins et
al., 2012). An interesting and contrasting consideration, however, finds that intracellular glucose
accumulation must not necessarily precede its uptake inhibition. Later studies conducted by
Roden et al. (1996) have suggested that glucose uptake is inhibited by increased plasma fatty
acids. These studies were further reinforced by the findings that INSRs are inhibited by the
activation of a number of kinases including protein kinase C (PKC), inhibitor of nuclear factor
kappa β (IKKβ), c-Jun N-terminal kinase (JNK), and p38 mitogen-activated protein (MAP)
kinase, through phosphorylation-mediated proteosome degradation (Martins et al., 2012).

Modern studies have described muscle insulin resistance induced via lipids including
diacylglycerols (DAGs), triacylglycerols (TAGs), and ceramides. Szebdridei et al. (2014) and Yu
and Pekkurnaz (2018) have demonstrated a marked increase in DAGs and PKCθ signaling,
which subsequently impairs IRS-1 activation via tyrosine phosphorylation (Martins et al., 2012).
As such, the IRS-1/PI3K/Akt signaling cascade is diminished, preventing insulin-stimulated
glucose uptake via GLUT proteins (Martins et al., 2012).

As obesity is a well-recognized risk factor for T2DM, an important consideration to its
development is both the amount and distribution of adipose tissue, which has autocrine,
paracrine, and endocrine functions in the secretion of various adipokines such as leptin,
adiponectin, resistin, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) (Pittas et al.,
2004). These adipokines can further be designated as insulin sensitizers and insulin antagonists.
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Of the insulin sensitizers, both leptin and adiponectin maintain an essential role in energy
homeostasis. Studies on leptin deficient (ob/ob) mice reveal conditions including obesity and
T2DM, the effect of which is reversed via the administration of leptin (Zhang et a., 1994). Leptin
has also been postulated to increase insulin sensitivity in peripheral tissues including the skeletal
muscle and liver (Unger et al., 1999 and Minokoshi et al., 2002). Similarly, adiponectin has been
shown to have a negative correlation with obesity (Arita et al., 1999), diabetic dyslipidemia
(Matsubara et al., 2002), and particularly with insulin resistance (Weyer et al., 2001). In another
model, administration of adiponectin to lipoatrophic mice reverses obesity and syndromes
associated with T2DM (Yamauchi et al., 2001).

The actions of insulin antagonists may also, at least to an extent, mediate T2DM. Resistin, for
example, has been shown to impair glucose tolerance and insulin action when administered in
normal mice, and while data still remain to be fully illustrated, suggests that resistin may impair
the actions of insulin on hepatic glucose production (Rajala et al., 2003). Similarly, mRNA of the
proinflammatory cytokine TNF-α has been shown to correlate positively with conditions
including hyperinsulinemia (Kern et al., 1995), possibly in part by facilitating increased free fatty
acid release by adipocytes and decreased adiponectin synthesis (Bruun et al., 2003). Lastly, IL-6,
another proinflammatory cytokine, is also partly responsible for decreasing insulin sensitivity by
mechanisms similar to TNF-α (Boden and Shulman, 2002 and Fasshauer et al., 2003) in mouse
models that developed obesity and glucose intolerance (Wallenius et al., 2002); however,
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evidence is conflicting in healthy human models who remained glucose-tolerant (Steensberg et
al., 2003).

While the exact mechanism has not been fully elucidated, hepatic insulin resistance is a major
contributor to systemic insulin resistance (Zhang et al., 2020), and insulin resistance in the
skeletal muscle and adipose tissue as previously described may stem from hepatic insulin
resistance (Badi et al., 2019). Hepatic insulin resistance follows a similar mechanism involving
DAGs, TAGs, and ceramides that accumulate in hepatic cells and stimulate PKC-ε, which in turn
downregulates insulin receptor kinase and IRS-1 and -2 tyrosine phosphorylation (Zhang et al.,
2020) as previously described. Hepatic insulin resistance and T2DM have been demonstrated to
be almost ubiquitous sequelae in individuals with non-alcoholic fatty liver disease (NAFLD), for
example, with greater than 90% of obese patients with NAFLD presenting with T2DM (Perry et
al., 2014). Given that hepatic DAG content along with other lipids are such strong predictors for
NAFLD with subsequent hepatic insulin resistance, regulation of fat delivery to the liver has
been a chief focus of biomedical research. Interestingly, Doege and colleagues (2008) have
found that knockdown of the primary fatty acid transporter in hepatocytes, fatty acid transporter
protein 5, via RNA interference demonstrated a marked reduction in fatty acid uptake in mice
that improved whole-body glucose homeostasis and reversed NAFLD, reinforcing the
contribution of lipids in the development of hepatic insulin resistance and T2DM.

12

1.2.4 Diabetes-Induced Vascular Dysfunction
The negative effects of glucose begin to occur at thresholds below hyperglycemic levels in a
concept known as the “glycemic continuum”, exacerbated by insulin resistance or impairment
and culminating in structural and functional endothelial (vascular) dysfunction: the impaired
production of endothelium-derived vasodilating and -constricting factors (Paneni et al., 2013 and
Daiber et al., 2017). Factors that mediate dilation include endothelium-derived relaxing factor
(EDRF), endothelium-derived hyperpolarizing factor (EDHF), prostacyclin, and of particular
interest, nitric oxide (NO), while the primary vasoconstricting factor is endothelin-I (Daiber et
al., 2017). One such causal link between hyperglycemia and decreased NO production is the
generation of reactive oxygen species (ROS) induced by hyperglycemia, contributing to polyol
flux, generation of advanced glycosylation end products (AGEs), PKC activation, and activation
of nuclear factor kappa light-chain enhancer of B cells (NF-κB) (Paneni et al., 2013). A
prominent contributor to ROS generation involves the aforementioned activation of PKC,
stemming from the elevation of DAG in a hyperglycemic endothelial environment and leading to
an increase in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-induced
superoxide production (Paneni et al., 2013). Indeed, ROS generation is a key contributor to
endothelial dysfunction, however, the bioavailability of NO, in particular, is affected as well via
the downregulation of endothelial nitric oxide synthase (eNOS) activity (Paneni et al., 2013),
limiting the dilatory capacity of the endothelium. It should be noted that ROS can also facilitate
endothelial dysfunction by directly scavenging NO or by eNOS uncoupling through the oxidative
phosphorylation of tetrahydrobiopterin (Funk et al., 2012). Further contributing to the generation
of ROS in hyperglycemic conditions is the retention of non-insulin-dependent GLUTs, in
contrast to insulin-dependent GLUTs, that are downregulated in these conditions. Non-insulin-
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dependent GLUTs allow for the constitutive uptake of extracellular glucose for enhanced
glycolytic oxidation and subsequent electron shuttling, stimulating oxidative stress and
downstream eNOS uncoupling (Funk et al., 2012).

Another prominent contribution to endothelial dysfunction involves the generation of
hyperglycemia-induced AGEs, the nonenzymatic addition of aldose carbohydrates to proteins in
a process termed the Milliard reaction (Funk et al., 2012). In this reaction, Schiff bases are
formed via the addition of a reducing sugar such as glucose or fructose to the α-amino group of
the N-terminus of a protein or to lysine, followed by rearrangement to form ketoamines and
subsequently AGEs via either oxidative or nonoxidative pathways (Funk et al., 2012). While
these products tend to have little clinical significance in healthy humans, hyperglycemia causes
excessive glycation of proteins found both in the serum (i.e., albumin) and in the vessel wall (i.e.,
collagen) (Funk et al., 2012). The formation of these modified proteins has deleterious effects on
eNOS coupling both directly and indirectly. In the former, AGEs facilitate the decrease in eNOS
expression and L-citrulline production while inhibiting histamine-induced NO production in the
latter (Funk et al., 2012).

1.3 Vascular Endothelium and Coronary Artery Anatomy
The common structure of a blood vessel comprises three layers: the tunica intima, tunica media,
and tunica adventitia (externa), which are composed of a single layer of endothelial cells, vascular
smooth muscle (VSM), and elastic lamina, respectively, from innermost to outermost
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(Dhananjayan et al., 2016). At its most basic level, the endothelium serves as a selectively
permeable barrier, regulating the transport of macromolecules between the lumen and VSM layer,
largely being restricted by interendothelial junctions at the endothelial cells’ lateral borders
(Cahill and Redmond, 2016). The endothelium is also largely responsible for the maintenance of
homeostatic functions via a precise balance between regulatory vasoactive factors such as NO,
endothelin-I, angiotensin and other adhesion molecules and cytokines (Dhananjayan et al., 2016).
Via these mechanisms, the endothelium tightly regulates blood flow, delivery of nutrients, and
inflammation (Dhananjayan et al., 2016). As such, these endogenous factors are implicated in
vascular responses that impact blood flow at a local level.

This thesis will focus exclusively on human endothelial cells of the coronary arteries and their
roles in vasodilation. The coronary arteries arise from the aorta within the left and right cusps of
the aortic valve to give rise to both the left main and right coronary arteries (LMCA and RCA),
respectively (Villa et al., 2016). The LMCA primarily supplies the left atrium and ventricle and
divides into two branches: the left anterior descending branch and the circumflex artery
(Ogobuiro et al., 2020). The RCA supplies the right atrium and ventricle, as well as the sinoatrial
and atrioventricular nodes, and divides into the right posterior descending branch and the acute
marginal artery (John’s Hopkins, 2020). Because there is a linear relationship between blood flow
and myocardial oxygen consumption (Saxton et al., 2020), and because of the endothelial
regulatory functions on vascular tone, it is important to understand the relationship between
dilatory substances such as NO and their role in the diseased state, such as in DM.

15

1.4 Nitric Oxide Synthase
While the VSM response to sympathetic stimulation largely contributes to vascular tone, namely
throughout the vascular tree (Cahill and Redmond, 2016), vascular tone and blood flow are both
highly regulated by NO, which is enzymatically formed by nitric oxide synthase (NOS) at a local
level (Chen et al., 2008). As such, the bioavailability of NO is totally dependent on NOS. To date,
there are three isoforms of NOS that have been elucidated: neuronal NOS (nNOS, NOS1),
inducible NOS (iNOS, NOS2), and eNOS (NOS3) (Chen et al., 2008). The latter represents a
pathway by which there are numerous stimuli for activation, including shear stress, vascular
endothelial growth factor (VEGF), estradiol, sphingosine 1-phosphate, and bradykinin, among
others, that act in calcium-dependent and -independent pathways (Sessa, 2014). In the former,
these stimuli can activate phospholipase C-γ, causing an increase in cytoplasmic calcium and
DAG concentrations (Sessa, 2014). The increased calcium subsequently activates calmodulin
(CaM), which binds to the CaM-binding domain on eNOS and stimulates the synthesis of NO
(Sessa, 2014). A number of these stimuli may also activate the PI3K/Akt pathway, one that is
calcium-independent and tightly controlled via a multistep process (Sessa, 2014).

1.5 PI3K/Akt/eNOS Pathway
PI3K is a heterodimeric protein containing a regulatory subunit and catalytic subunit known as
p85 and p110, respectively (Cantrell, 2001), and is involved in a wide-range of cellular processes
including protein synthesis, trafficking, regulation of enzyme activity, and proliferation, among
others (Ciraolo et al., 2014). The activation of PI3K begins with binding of receptor tyrosine
kinases (RTKs), which can be facilitated by a number of stimuli, including hormones, growth
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factors, and components of the extracellular matrix (Nicholson et al., 2002), as well as through
transactivation via the Gα subunit of G-protein coupled receptors (GPCRs) (New et al., 2011).
Upon binding of these substances to the extracellular N-terminal domain or through activation via
Gα, RTKs undergo dimerization and autophosphorylation of the tyrosine residues in the
intracellular domain (Shi et al., 2019). Subsequently, PI3K is recruited to the membrane by the
p85 subunit, the Src homology 2 (SH2) domain of which binds the pYXXM motif of the tyrosinephosphorylated RTK (Jiang et al., 2014), followed by recruitment of the p110 subunit (Liu et al.,
2009). It should be noted that there are three other pathways that can activate PI3K as well: in the
first, the pYXXM-bound growth factor receptor-bound protein 2 (GRB2) binds GRB2-associated
binding protein (GAB), which in turn binds the p85 subunit of PI3K (Castellano and Downward,
2011) followed by recruitment of p110. In the second, the pYXXM-bound GRB2 binds the
guanine nucleotide exchange factor Son of Sevenless (SOS), which in turn binds and activates
RAS, and finally activates the p110 subunit of PI3K without the need for p85 (Castellano and
Downward, 2011). Lastly, the p110 subunit of PI3K can be directly activated by the Gβγ subunit
of GPCRs (New et al., 2011).

The activation of PI3K subsequently yields phosphorylation of phosphatidylinositol 4,5bisphosphate (PIP2) forming phosphatidylinositol 3,4,5-triphosphate (PIP3), and provides
docking sites for proteins such as Akt (Liu et al., 2009). Because of its high affinity for PIP3
(Miao et al., 2010), the pleckstrin homology (PH) domain of Akt translocates to PIP3 on the
membrane and induces conformational changes on Akt that exposes residues Thr308 and Ser473. It
is important to note that full activation of Akt requires phosphorylation of both of these residues,
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Thr308 being phosphorylated by phosphoinositide-dependent kinase 1 (PDK1) (Dangelmaier et al.,
2014), and Ser473 phosphorylated by phosphoinositide-dependent kinase 2 (PDK2), integrinlinked kinase (ILK) (Osaki et al., 2004), mechanistic target of rapamycin complex (mTORC)
(Sarbassov et al., 2005), and DNA-dependent protein kinase (DNA-PK) (Feng et al., 2004).

Upon full activation of Akt, the downstream effector, eNOS, can be phosphorylated at a number
of residues, thereby increasing or decreasing eNOS activity, and thus have opposing effects. For
example, the Thr495 domain acts as an inhibitory site while Ser635 and Ser1177 act as activation sites
(Zhao et al., 2015). Activation of eNOS through Ser635 or Ser1177 subsequently yields catalysis of
the five-electron oxidation of a guanidine nitrogen on L-arginine, yielding NO and L-citrulline as
a byproduct (Barbato and Tzeng, 2004) in the presence of molecular oxygen and NADPH (Chen
et al., 2008). (Figure 1).

Figure 1.

Schematic of the PI3K/Akt/eNOS pathway and NO-mediated vasodilation. * = PDK2, ILK,
mTORC, DNA-PK; ** = PDK1.
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1.6 Nitric Oxide-Mediated Vasodilation
Upon diffusion from the endothelium to the VSM, NO binds an N-terminal heme moiety of its
heterodimeric primary receptor, soluble guanylate cyclase (sGC) (Montfort et al., 2017). This
binding forms a penta-coordinated iron-NO complex (Pan et al., 2017) and subsequently converts
guanosine triphosphate (GTP) to a second messenger, guanosine 3,5-cyclic monophosphate
(cGMP), initiating the cGMP signaling pathway (Pasmanter et al., 2020) and resulting in protein
kinase G (PKG) activation (Francis et al., 2010).

PKG ultimately induces VSM relaxation through three individual mechanisms: 1)
phosphorylation of L-type calcium channels, thus reducing calcium influx and preventing
contraction (Takimoto and Kass, 2012); 2) phosphorylation of ATP-sensitive potassium channels
resulting in hyperpolarization (Han et al., 2002); and 3) phosphorylation of myosin light chain
phosphatase (MLCP), which in turn dephosphorylates myosin light chain kinase (MLCK), thus
preventing the cross-bridge action of actin and myosin, yielding vasorelaxation (Landry et al.,
2006) (Figure 1).

1.7 Allicin and Garlic-Derived Sulfides
Alliin is an inactive sulfoxide that is derived from the hydrolysis or oxidation of γglutamylcysteine found in raw, dietary garlic (Allium sativum) (Amagase et al., 2001). Upon
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ingestion, there is activation of the garlic-derived allinase enzyme, which converts the inactive
alliin into its active form called diallyl thiosulfinate (or allicin) (Amagase et al., 2001). This
unstable active compound readily breaks down into three organic polysulfides: diallyl sulfide
(DAS), diallyl disulfide (DADS), and diallyl trisulfide (DATS) (Banerjee and Maulik, 2002).
Furthermore, previous research indicates that these polysulfides produce hydrogen sulfide (H2S)
via thiol-dependent cellular and glutathione (GSH)-dependent acellular reactions (Benadives et
al., 2007). While H2S is well-known to be a toxic gas that is produced endogenously via Lcysteine (Hosoki et al., 1997), Predmore et al. (2011) have demonstrated that H2S upregulates NO
production via an Akt-dependent mechanism in bovine arterial endothelial cells (BAECs).

1.8 Preliminary Data
Horuzsko et al. (2019) have demonstrated that treatment of healthy human donor coronary artery
endothelial cells (HCAEC), type-I diabetic human donor coronary artery endothelial cells
(DHCAEC-I), and type-II diabetic human donor coronary artery endothelial cells (DHCAEC-II)
with allicin increases NO production in DHCAEC-I but not in HCAEC nor DHCAEC-II. As
measured by EVOS imaging, allicin increased mean fluorescence intensity in DHCAEC-I by
>292% compared to untreated cells, indicating an increase in NO production. Further,
immunoblot analysis revealed that there was no statistically-significant difference in untreated
vs. treated HCAEC or DHCAEC-II eNOS expression; however, eNOS expression in DHCAEC-I
increased by approximately 26% when treated with 5 μM allicin overnight. Given that NO
production follows the required phosphorylation at a positively-regulating motif on eNOS, these
data suggest that allicin mediates the restoration of NO and is eNOS-dependent.
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1.9 Proposed Pathway
Previous literature has supported that garlic-derived polysulfides induce H2S production via a
thiol-dependent manner. The unstable active allicin readily breaks down into DAS, DADS, and
DATS in vivo and in vitro and act as H2S donors when reacting with biological thiols such as
GSH (Benavides et al., 2007). Further, treatment of BAECs with H2S has demonstrated a timedependent 87% increase in NO production at 30 minutes post-treatment, and because it is not
elevated at subsequent times, this suggests a transient activation of eNOS (Predmore et al., 2011),
which may possibly be attributed to changes in the enzyme’s phosphorylation status. Data
strongly suggest that the phosphorylation of eNOS surrounding the Ser1177 motif (RIRTQS1177F)
is a result of upstream activation of Akt, which is a downstream target of PI3K (Michell et al.,
1999). In BAECs treated with H2S, the Akt inhibitor triciribine prevented an increase in
eNOSSer1177 phosphorylation, suggesting that H2S stimulates eNOS phosphorylation via an Aktdependent mechanism (Predmore et al., 2011). Further, attenuation of PI3K with the inhibitor
wortmannin has demonstrated a decrease in the phosphorylation of PI3K, Akt, and eNOS (Song
et al., 2016), lending support to the pathway proposed herein.

In summary, it is proposed that allicin-derived polysulfides stimulate the PI3K/Akt pathway and
result in downstream phosphorylation of eNOS at the Ser1177 motif, this pathway being
responsible for increased NO production in DHCAEC-I.
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METHODS
2.1 Cell Culture
Passage (P) 2 HCAEC (Lonza) and DHCAEC-I (Lonza) from a 21-year-old (y.o) male donor and
a 29 y.o female donor, respectively, were removed from liquid nitrogen in sterile cryovials
combined with dimethyl sulfoxide (DMSO) and grown in 5 mL endothelial cell basal growth
media (EBM-2, Lonza) and supplemented with microvascular endothelial SingleQuots kit
(Lonza) and 1% penicillin/streptomycin at 37 °C and 5% CO2 until a confluence of ≥90% was
reached. Both cell types were subsequently passaged via the addition of 0.25% trypsin/EDTA
(1X, Thermo Fischer) and incubated at 37 °C for 3 minutes to facilitate cell detachment. Once the
cells were fully detached, fresh EBM-2 was added, and cells were divided between 3 flasks and
re-incubated. To maintain an optimal growth environment, cell media was exchanged every two
days.

2.2 Hydrogen Sulfide Production
2.2.1 Mechanism of SF7-AM
Sulfidefluor-7 acetoxymethyl ester (SF7-AM, Cayman Chemical) is a membrane-permeable,
non-fluorescent indicator of H2S production. Upon entry into the cell, the acetoxymethyl ester
groups are hydrolyzed by intracellular esterases, yielding a negatively-charged SF7, rendering
the compound membrane-impermeable and thus remaining trapped inside the cell (Lin et al.,
2013). Once trapped inside the cell, SF7 is weakly-fluorescent; however, in the presence of H2S,
the azide functional groups are reduced to primary amines, forming a highly-fluorescent
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derivative (SF7-D) (Lin et al., 2013), allowing for relative quantifications of H2S at nanomolar
concentrations. (Figure 2).

Figure 2.

Schematic of the mechanism for SF7-AM.

2.2.2 Baseline Hydrogen Sulfide Imaging
Aliquots of 1.5 mL P4 HCAEC and DHCAEC-I were plated separately in groups of three until a
confluence of 60% was reached, with the following conditions: 1) untreated; 2) treated with 5 μM
allicin (Table 1). 24 hours prior to imaging, the EBM-2 was aspirated and replaced with 1.5 mL
phenol red free EBM-2 (PRFM, Lonza). 500 μL 2.5 μM SF7-AM/PRFM was added to the cells
under a dark hood and incubated in the dark at 37 °C and 5% CO2 for 30 minutes followed by
aspiration and washing three times with 1 mL PRFM. For baseline imaging, cells were incubated
for 30 minutes once more with 500 μL PRFM and imaged using an EVOS microscope at 40X
with a GFP filter (ex/em 498/526 nm).
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Untreated
Table 1.

HCAEC

+ 5 μM allicin

Untreated

DHCAEC-I

+ 5 μΜ allicin

Experimental design and treatment allocation for the measurement of H2S.

2.2.3 Allicin Treatment Hydrogen Sulfide Imaging
After baseline imaging, cells were washed three times with 1 mL PRFM. After the last wash, cells
were treated with 500 μL 5 μM allicin (Santa Cruz Biotechnology)/PRFM and incubated in the
dark at 37 °C and 5 % CO2 for 20 minutes. Images were captured at 40X with a GFP filter (ex/em
498/526 nm). The calculation for allicin dilution is shown below:
10 𝑚𝑚𝑚𝑚 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎
1 𝑔𝑔
1000 𝑚𝑚𝑚𝑚
1 𝑚𝑚𝑚𝑚𝑚𝑚
10,000
∗
∗
∗
=
= 0.0616256 𝑀𝑀
𝑚𝑚𝑚𝑚
1000 𝑚𝑚𝑚𝑚
1 𝐿𝐿
162.27 𝑔𝑔 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 162,270
= 61.6256 𝑚𝑚𝑚𝑚 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎

1: 10 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 = 10 𝜇𝜇𝜇𝜇 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 + 90 𝜇𝜇𝜇𝜇 𝑑𝑑𝑑𝑑𝑑𝑑2 𝑂𝑂 = 6.16256 𝑚𝑚𝑚𝑚 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠

𝑉𝑉1 =

𝐶𝐶2 𝑉𝑉2 (0.005 𝑚𝑚𝑚𝑚 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐)(2 𝑚𝑚𝑚𝑚 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣)
=
𝐶𝐶1
6.16256 𝑚𝑚𝑚𝑚 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠

= 0.0016227 𝑚𝑚𝑚𝑚 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 = 1.6227 𝜇𝜇𝐿𝐿 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑖𝑖𝑖𝑖 2 𝑚𝑚𝑚𝑚 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃 = 5 𝜇𝜇𝑀𝑀 𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎
2.3 Nitric Oxide Production
2.3.1 Mechanism of DAF-FM DA
4-amino-5-methylamino-2’, 7’-difluorofluorescein diacetate (DAF-FM DA, Thermo Fischer) is a
membrane-permeable, non-fluorescent indicator of NO production. Upon entry into the cell, the
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acetate groups are hydrolyzed by intracellular esterases, yielding a negatively-charged DAF-FM,
rendering the compound membrane-impermeable and thus remaining trapped inside the cell
(Cortese-Krott et al., 2012). Once trapped inside the cell, DAF-FM is weakly-fluorescent;
however, in the presence of NO and oxygen (NO• + O2  N2O3), a highly-fluorescent
benzotriazole derivative (DAF-BT D) is formed (Cortese-Krott et al., 2012), allowing for relative
quantifications of NO at nanomolar concentrations (Ghebremariam et al., 2013) (Figure 3).

Figure 3.

Schematic of the mechanism for DAF-FM DA.

2.3.2 Baseline Nitric Oxide Imaging
Aliquots of 1.5 mL P4 HCAEC and DHCAEC-I were plated separately in groups of three until a
confluence of 60% was reached, with the following conditions: 1) untreated; 2) treated with 5 μM
allicin; 3) pretreated with 5 μM wortmannin (an inhibitor of PI3K; Sigma Aldrich) followed by
treatment with 5 μM allicin (Table 2). 24 hours prior to imaging, the EBM-2 was aspirated and
replaced with 1.5 mL PRFM. 500 μL 10 μM DAF FM-DA/PRFM was added to the cells under a
dark hood and incubated in the dark at 37 °C and 5% CO2 for 30 minutes followed by aspiration
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and washing three times with 1 mL PRFM. For baseline imaging, cells were incubated for 30
minutes once more with 500 μL PRFM and imaged using an EVOS microscope at 40X with a
GFP filter (ex/em 495/515 nm).

Untreated

Table 2.

HCAEC

+ 5 μM allicin

+ 5 μM WRT +
5 μM allicin

Untreated

DHCAEC-I

+ 5 μM allicin

+ 5 μM WRT +
5 μM allicin

Experimental design and treatment allocation for the measurement of NO. WRT = wortmannin.

2.3.3 Allicin Treatment Nitric Oxide Imaging
After baseline imaging, cells were washed three times with 1 mL PRFM. After the last wash, cells
were treated with 500 μL 5 μM allicin/PRFM and incubated in the dark at 37 °C and 5 % CO2 for
20 minutes. Images were captured at 40X with a GFP filter (ex/em 495/515 nm).

2.3.4 Wortmannin Pretreatment Nitric Oxide Imaging
To measure the effects of PI3K inhibition, cells were incubated with 500 μL 10 μM DAF-FM
DA/PRFM for 30 minutes at 37 °C and 5 % CO2, followed by aspiration and washing three times
with 1 mL PRFM. Subsequently, cells were incubated with 500 μL 5 μM wortmannin for 30
minutes, aspirated and washed three times with 1 mL PRFM, and incubated for 20 minutes with
500 μL 5 μM allicin at 37 °C and 5 % CO2. Cells were imaged using an EVOS microscope at 40X
with a GFP filter (ex/em 495/515 nm).
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2.4 Phospho-eNOS and Phospho-Akt Immunoblots
P4 HCAEC and DHCAEC-I were grown in sets of three separate 100 mm cell culture dishes to
≥90% confluence in 10 mL EBM-2. Prior to protein collection, one dish of each set remained
untreated with 10 mL PRFM only, one received 10 mL 5 μM allicin/PRFM, and one was
pretreated with 10 mL 5 μM wortmannin for 30 minutes followed by addition of 8.113 μL allicin
(final concentration = 5 μΜ) (Table 3). The three culture dishes of each cell type were
subsequently incubated for 20 minutes at 37 °C and 5% CO2 followed by washing with 25 mL 1X
phosphate buffered saline (PBS).

Cells were lysed with 100 μL ice cold 1X radioimmunoprecipitation assay (RIPA) lysis buffer
(Thermo Fischer) for 1 hour on ice and centrifuged at 21,754 g for 10 minutes. Cell supernatants
were transferred to new Eppendorf tubes and protein concentrations were determined with a
Pierce bicinchoninic acid kit (Thermo Fischer). Samples were prepared by combining 70 μg of
protein with 10 μL 4X Laemmli Sample Buffer (Bio-Rad) and 1X PBS to a total volume of 40
μL, followed by boiling at approximately 95 °C for 5 minutes. 40 μL of the samples were loaded
in Mini-PROTEAN TGX 4-20% 10-well precast gels (Bio-Rad). Sodium dodecyl sulfide
polyacrylamide gel electrophoresis (SDS-PAGE) of both treated and untreated HCAEC and
DHCAEC-I were carried out in triplicate with 1X Tris/Glycine/SDS buffer (Bio-Rad) for
approximately 2 hours at 100 V followed by transfer to a polyvinylidene difluoride (PVDF)
membrane using a Bio-Rad Trans-Blot Turbo Transfer System in 1X Trans-Blot Turbo Transfer
Buffer (Bio-Rad). PVDF membranes were then rinsed with and washed in 1X PBS with 1%
Tween20 (Fischer BioReagents, PBST) for 5 minutes while shaking at room temperature,
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followed by incubation with Odyssey Blocking Buffer in PBS (Li-Cor) for 1 hour while shaking
at room temperature.

Primary antibodies against phospho-eNOSSer1177 (rabbit, monoclonal, Invitrogen, 1:1000 dilution),
eNOS (mouse, monoclonal, BD Biosciences, 1:700 dilution), phospho-AktSer473 (mouse,
monoclonal, Proteintech, 1:1000 dilution), Akt (mouse, monoclonal, Proteintech, 1:2000
dilution), and β-actin (mouse, monoclonal, Li-Cor, 1:5000 dilution) were diluted in 5 mL Odyssey
Blocking Buffer with 10% Tween20 and incubated with the PVDF membranes overnight while
shaking at 4 °C. On the following day, the membranes were incubated for one additional hour
while shaking at room temperature and subsequently washed three times with PBST: once for 15
minutes and twice more for 5 minutes. After washing, the membranes were incubated with a goat
anti-rabbit or goat anti-mouse antibody (monoclonal, Li-Cor, 1:5000 dilution) solution in 5 mL
Odyssey Blocking Buffer, 10% SDS, and 10% Tween20 for 1 hour while shaking at room
temperature. Following incubation with secondary antibody, membranes were washed three times
with PBST: once for 15 minutes and twice more for 5 minutes, and PBS twice for 5 minutes.
Membranes were visualized using a Li-Cor Odyssey CLx Imaging System.

Untreated

Table 3.

HCAEC

+ 5 μM allicin

+ 5 μM WRT +
5 μM allicin

Untreated

DHCAEC-I

+ 5 μM allicin

+ 5 μM WRT +
5 μM allicin

Experimental design and treatment allocation for the measurement of p-eNOSSer1177 and pAktSer473. WRT = wortmannin.
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2.5 Statistical Analysis
All experiments were conducted on three separate days with three separate cultures for statistical
purposes and data are expressed as means ± SD. Pixel intensity for all EVOS data and
immunoblot data were assessed using ImageJ software. H2S data were analyzed via paired t-test;
NO data, phospho-eNOSSer1177 immunoblot data, and phospho-AktSer473 immunoblot data were
analyzed via one-way ANOVA with Tukey’s post-hoc; total eNOS expression comparisons were
analyzed via two-sample t-test. Graphs were generated using GraphPad Prism software.
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RESULTS
3.1 Allicin stimulates H2S production in HCAEC and DHCAEC-I
Allicin stimulated H2S production in both HCAEC and DHCAEC-I as indicated by SF7 mean
fluorescence intensity (MFI). Baseline SF7 MFI in HCAEC was 27.412 ± 2.462 arbitrary units
(AU; n = 3) and increased after addition of 5 μM allicin to 61.953 ± 5.712 AU (p < 0.01
compared to baseline; n = 3), representing a 126% increase in H2S production. In DHCAEC-I,
baseline SF7 MFI was 37.211 ± 3.557 AU (n = 3), which increased by 85% after the addition of
5 μM allicin (68.945 ± 4.248 AU; p < 0.01 compared to baseline; n = 3). Data are expressed as
mean ± SD. Student’s paired t-test was performed. (Figure 4).

Figure 4.

H2S production in HCAEC and DHCAEC-I detected by SF7-AM. A) Representative
fluorescence microscopy images of HCAEC and DHCAEC-I at baseline, prior to allicin treatment
(Bs) and after 20-minute treatment with 5 μM allicin (All). B) Quantification of relative H2S
production through mean fluorescence intensity. Results are displayed as mean ± SD. ** = p <
0.01.
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3.2 Allicin stimulates NO production and wortmannin reverses this effect in DHCAEC-I
Allicin stimulated NO production in DHCAEC-I and PI3K inhibition by wortmannin prevented
an increase in NO production. In DHCAEC-I, baseline DAF fluorescence was 12.468 ± 0.468
AU, and 5 μM allicin treatment increased MFI by 66% (20.798 ± 0.403 AU; p < 0.0001
compared to baseline; n = 3). In cells pretreated with 5 μM wortmannin followed by allicin
treatment, this effect was diminished with a MFI of 11.070 ± 0.451 AU (p < 0.0001 compared to
allicin only; p < 0.05 compared to baseline; n = 3). (Figure 5).

In HCAEC, baseline MFI was 12.110 ± 0.105 AU (n = 3), and 11.718 ± 0.643 AU (p < 0.50
compared to baseline; n = 3) after treatment with 5 μΜ allicin. In cells pretreated with 5 μM
wortmannin followed by 5 μM allicin, MFI was 10.795 ± 0.445 AU (p < 0.05 compared to
allicin only; p < 0.01 compared to baseline; n = 3). All data are expressed as mean ± SD. Oneway ANOVA with Tukey’s post-hoc was performed. (Figure 5).
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Figure 5.

NO production in HCAEC and DHCAEC-I detected by DAF-FM DA. A) Representative
fluorescence microscopy images of HCAEC and DHCAEC-I at baseline, prior to allicin treatment
(Bs), after 20-minute treatment with 5 μM allicin (All), and after 5 μM allicin treatment in cells
pretreated with 5 μM wortmannin (W). B) Quantification of relative NO production through mean
fluorescence intensity. Results are displayed as mean ± SD. * = p < 0.05, ** = p < 0.01, **** = p
< 0.0001.

3.3 Allicin increases eNOSSer1177 phosphorylation and wortmannin reverses this effect in
DHCAEC-I
Allicin treatment of DHCAEC-I with 5 μM allicin increased eNOS phosphorylation at Ser1177
from baseline (0.496 ± 0.087 AU; n = 3) to 0.938 ± 0.184 AU (p < 0.05 compared to baseline; n
= 3), representing an 89% increase in eNOS phosphorylation. However, in DHCAEC-I
pretreated with 5 μM wortmannin, the effect of allicin was diminished, returning MFI to levels
similar to baseline (0.245 ± 0.113 AU; p < 0.01 compared to allicin only; p < 0.13 compared to
baseline; n = 3). (Figure 6).
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In HCAEC, allicin had no effect on eNOSSer1177 phosphorylation (0.904 ± 0.361 AU; n = 3)
compared to baseline (0.967 ± 0.235 AU; p < 0.95; n = 3). Similarly, in HCAEC pretreated with
5 μΜ wortmannin, allicin did not increase phosphorylation (0.671 ± 0.166 AU; p < 0.56
compared to allicin only; p < 0.41 compared to baseline; n = 3). All phospho-eNOSSer1177 data
are expressed as mean ± SD. β-actin was used as a loading control for all immunoblots. One-way
ANOVA with Tukey’s post-hoc was performed. (Figure 6).

Lastly, total eNOS expression was elevated in DHCAEC-I compared to HCAEC. Mean total
eNOS expression (eNOS/β-actin) in HCAEC at baseline was 0.438 ± 0.005 AU (n = 3)
compared to 0.803 ± 0.071 AU in DHCAEC-I (p < 0.001; n = 3). All total eNOS expression data
are expressed as mean ± SD. Student’s two-sample t-test was performed. (Figure 6).
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Figure 6.

Phosphorylation of eNOSSer1177 in HCAEC and DHCAEC-I. A) Representative immunoblot
analysis for p-eNOSSer1177 and total eNOS in HCAEC and DHCAEC-I at baseline, prior to allicin
treatment (Bs), after 20-minute treatment with 5 μM allicin (All), and after 5 μM allicin treatment
in cells pretreated with 5 μM wortmannin (W). B) Quantification of eNOSSer1177 phosphorylation
relative to total eNOS through mean band intensity. C) Quantification of total eNOS expression
relative to β-actin at baseline through mean band intensity. Results are displayed as mean ± SD. *
= p < 0.05, ** = p < 0.01, *** = p < 0.001.

3.4 Allicin has no statistically-significant effect on AktSer473 phosphorylation
5 μM allicin treatment of HCAEC decreased phosphorylation of AktSer473 from 1.618 ± 0.310
AU (n = 3) to 1.476 ± 0.396 AU (p < 0.87 compared to baseline; n = 3). Further, in HCAEC
pretreated with 5 μM wortmannin followed by 5 μM allicin treatment, mean band intensity
(MBI) was 1.436 ± 0.337 AU (p < 0.98 compared to allicin only; p < 0.80 compared to baseline;
n = 3). In DHCAEC-I, 5 μM allicin treatment increased AktSer473 phosphorylation from baseline
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(1.151 ± 0.323 AU) to 1.301 ± 0.324 AU (p < 0.82; n = 3); however, these data were not
statistically-significant. With pretreatment of 5 μΜ wortmannin followed by 5 μM allicin, MBI
was 1.010 ± 0.274 AU (p < 0.51 compared to allicin only; p < 0.84 compared to baseline; n = 3).
All data are expressed as mean ± SD. β-actin was used as a loading control for all immunoblots.
One-way ANOVA with Tukey’s post-hoc was performed. (Figure 7).

Figure 7.

Phosphorylation of AktSer473 in HCAEC and DHCAEC-I. A) Representative immunoblot analysis
for p-AktSer473 in HCAEC and DHCAEC-I at baseline, prior to allicin treatment (Bs), after 20minute treatment with 5 μM allicin (All), and after 5 μM allicin treatment in cells pretreated with
5 μM wortmannin (W). B) Quantification of AktSer473 phosphorylation relative to total Akt through
mean band intensity. Results are displayed as mean ± SD.
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DISCUSSION
HCAEC play a principal role in the maintenance of endothelial/vascular health through the
balance of vasodilating (NO, EDRF, EDHF, prostacyclin) and constricting factors (endothelin-I).
However, insults to vascular integrity increases the risk for pro-atherogenic effects and
manifestations related to the development of CVD, exacerbated by factors such as ROS and
AGEs. The chief endothelium-derived factor for maintaining hemodynamic homeostasis is NO;
as T1DM and T2DM increase the likelihood for the aforementioned CVDs stemming from DMinduced endothelial dysfunction, new interventions are being explored. With respect to naturallyoccurring allyl thiosulfinates, allicin is the most abundant and studied member and has
demonstrated lipid-lowering, antioxidant, anti-atherosclerotic, and anticancer effects (Lawson
and Hunsaker, 2018). Horuzsko et al. (2019) have demonstrated that allicin alleviates endothelial
dysfunction by increasing NO in DHCAEC-I; however, the mechanism of action remained to be
elucidated. Here, we have demonstrated that allicin exerts its effects on eNOSSer1177
phosphorylation via a PI3K-dependent mechanism. Allicin significantly increased NO
production (p < 0.0001) and eNOSSer1177 phosphorylation (p < 0.05), the effects of which were
reversed by inhibiting PI3K via the use of wortmannin (p < 0.0001 and p < 0.01, respectively) in
DHCAEC-I.

These data provide strong implications on the alleviation of endothelial dysfunction via
increasing eNOS-dependent NO production and build on previous findings by Ma et al. (2018).
Their particular study suggested that allicin attenuates apoptosis induced by ischemic or hypoxic
events in H9c2 myoblasts through eNOS. It was shown that treatment of H9c2 myoblasts with
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allicin significantly reversed the effects of intermittent hypoxia-induced increases in
malondialdehyde and decreases in superoxide dismutase; further, these effects of allicin were
diminished by the use of L-arginine methyl ester (L-NAME), an inhibitor of eNOS activity,
reinforcing the involvement of eNOS in allicin-mediated cardioprotection (Ma et al., 2018).
Moreover, allicin has been linked to improvements in cardiac functions by reducing
cardiomyocyte size and decreasing B-type natriuretic peptide (BNP) and β-myosin heavy chain
(β-MHC) (Ba et al., 2019). BNP, a hormone secreted by ventricular cardiomyocytes in response
to stretch (Novack and Zevitz, 2020), and β-MHC, the major protein comprising myosin in
cardiomyocytes (Krenz and Robbins, 2004), both serve as biomarkers for hypertrophic
cardiomyopathy. Ba et al. (2019) have demonstrated that expression of both BNP and β-MHC
from cardiomyocytes in rats with cardiac hypertrophy decreased after treatment with allicin,
underscoring the hypertrophic relief provided by our compound of interest.

In our study, while NO production and phosphorylation of eNOSSer1177 increased in DHCAEC-I
after treatment with 5 μM allicin (p < 0.0001 and p < 0.05, respectively), it should be noted that
we did not observe this effect in HCAEC. We currently propose two different hypotheses for
these findings: 1) given that HCAEC are presumed to be healthy with no indications of
endothelial dysfunction, it is plausible that any treatments to increase NO may not have a
significant difference in cells with an optimal level of NO production and eNOSSer1177
phosphorylation. For example, we see that the mean band intensity in the immunoblots targeting
p-eNOSSer1177 is 0.967 ± 0.275 AU in HCAEC, while that of DHCAEC-I is 0.496 ± 0.087 AU –
approximately 48% less than baseline phosphorylation in HCAEC. 2) As there are varying
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mechanisms to stimulate eNOS, it is possible that different cell types may use different pathways
or motifs in these phosphorylation cascades. For one, eNOS phosphorylation can occur at a
number of motifs that may be activating or deactivating: aside from Ser1177, Ser1179, Ser633, and
Ser615 all participate in positive regulation of eNOS (Rafikov et al., 2011). However, this second
suggestion does not account for the fact that we did not see an increase in NO production under
fluorescence microscopy.

Notably, we discovered a marked difference between baseline expressions of eNOS between
HCAEC and DHCAEC-I. In DHCAEC-I, baseline total eNOS expression was approximately
83% higher compared to HCAEC. We hypothesize that this is likely due to a mechanism in
DHCAEC-I to compensate for the reduced bioavailability of NO that is typically seen in DMinduced endothelial dysfunction. These suggestions stem from data collected by Takahashi and
Harris (2014) in which eNOS expression was found to be increased early after the onset of
diabetes and decreased with the disease’s progression. Many cases of endothelial dysfunction,
particularly in DM, are accompanied by an upregulation of eNOS expression, likely as a (futile)
counter-regulatory mechanism that ultimately results in superoxide anion production in lieu of
NO (Li et al., 2002 and Musicki and Burnett, 2007). We therefore suspect that the notable
increase in total eNOS expression seen in DHCAEC-I compared to HCAEC is the result of a
compensatory mechanism to increase baseline NO production.

Another very interesting finding from our research was that we did not see a significant change
in AktSer473 phosphorylation as we initially expected. We hypothesized that activation of PI3K
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would stimulate PIP2/PIP3 and subsequently the phosphorylation of Akt at Ser473 and Thr308. As
previously described, full activation of Akt requires the phosphorylation of both residues, and as
such, we expected to observe an increase in the phosphorylation of AktSer473 given that PI3K is
clearly involved in this pathway. We now suspect the possibility that AktSer473 may not be
directly associated with an increase in PI3K-dependent phosphorylation after stimulation with
allicin in DHCAEC-I. This suggestion stems from the work conducted by Kobayashi et al.
(2009) in which internal mammary artery endothelial cells with experimental insulin resistance
demonstrated that the Thr308 site of Akt was significantly impaired, whereas that of total Akt
expression and phosphorylation at the Ser473 site were not affected, thus directly contradicting
our initial expectations and supporting this new notion. As such, the phosphorylation of Thr308 by
PDK1 is likely more closely tied with insulin impairment, providing a likely explanation for our
data. Given this newfound information, our future studies involving this pathway will be closely
targeted on measuring the phosphorylation at AktThr308 as opposed to Ser473. It should also be
noted that our initial proposal included the use of the triciribine, which prevents the activation,
phosphorylation, and signaling of Akt, in our NO fluorescence microcopy and eNOSSer1177
immunoblot experiments; however, we were unable to obtain this inhibitor to confirm Akt’s
involvement.

One of the major potential contributors to the allicin-mediated activation of PI3K that results in
downstream phosphorylation of eNOS and subsequent NO production is the generation of H2S.
As allicin is a relatively unstable compound, it readily breaks down into three organic
polysulfides: DAS, DADS, and DATS, which have previously been shown to produce H2S via
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thiol-dependent cellular and glutathione (GSH)-dependent acellular reactions (Benavides et al.,
2007). We have successfully demonstrated that allicin results in a significant increase in H2S
production in both HCAEC and DHCAEC-I (p < 0.01); however, we have not elucidated the
mechanism nor role of H2S in this pathway. Given that the vasodilatory effects of allicin were
reversed in DHCAEC-I pretreated with a PI3K inhibitor, we suspect that H2S is likely
stimulating PI3K, either directly or indirectly. This assumption correlates with a number of
studies, including one conducted by Lin and colleagues (2020), in which H2S was found to
alleviate hyperglycemia-induced inactivation of the PI3K/Akt/eNOS pathway in human
umbilical vein endothelial cells (HUVECs). In this particular study, normoglycemic (control)
HUVECs had p-PI3K/PI3K, p-Akt/Akt, and p-eNOS/eNOS ratios ranging between 0.75 to 0.85;
however, exposure of these cells to hyperglycemic conditions reduced all ratios by >50%, and
administration of NaHS (a H2S donor) returned all ratios to near normoglycemic levels of
phosphorylation. Moreover, these data reinforce studies conducted by Manna and Jain (2011) in
which high glucose-induced decreases in PI3K and increases in phosphatase and tensin homolog
(PTEN; a negative regulator of PI3K) were reversed via treatment with H2S in adipocytes.

Given that PI3K phosphorylation can be mediated by RTKs (among other pathways), we now
suspect that H2S is directly stimulating vascular endothelial growth factor receptor subtype 2
(VEGFR2), a RTK on the endothelial cell surface. Data collected by Tao et al. (2013)
demonstrated that H2S could directly activate VEGFR2, and small interfering RNA (siRNA)
knockdown of VEGFR2 prevented downstream phosphorylation of PI3K. VEGFR2 contains an
intracellular disulfide bond between Cys1045-Cys1024 that serves as an inhibitory motif.
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However, upon diffusion into the cell, H2S reduces the Cys1045-Cys1024 bond (S–S  Cys–SH
+ HS–SH) via nucleophilic attack, diminishing the inhibitory consequences of the bond (Tao et
al., 2013) and allowing for subsequent dimerization and autophosphorylation that is typical in
RTKs, resulting in downstream PI3K activation. We therefore propose that allicin-derived H2S is
functioning as a “molecular switch”, reducing the Cys1045-Cys1024 bond in VEGFR2 and
mediating the PI3K-dependent phosphorylation of eNOSSer1177.

While we have indeed demonstrated that PI3K is involved in allicin-mediated phosphorylation of
eNOS, it is worthy to note that allicin-derived H2S may also target eNOS directly though Ssulfhydration, a posttranslational modification that targets cysteine residues (Altaany et al.,
2014). S-nitrosylation, the covalent attachment of NO to the thiol group of cysteine residues (Qin
et al., 2013), reversibly attenuates eNOS activity (Wang et al., 2019). Interestingly, Altaany et al.
(2014) have found that S-sulfhydration and S-nitrosylation competitively modify eNOS at Cys443
and that S-sulfhydration of eNOS decreases S-nitrosylation at the same residue. While Ssulfhydration after NaHS treatment does not directly cause phosphorylation of eNOS, it does
indirectly promote its phosphorylation by inhibiting the NO-induced concentration-dependent Snitrosylation (Altaany et al., 2014).

Given its structure, and as previously described, allicin is readily unstable and ultimately breaks
down into polysulfides in both aqueous and ethanoic solutions. Our allicin stock solution was
supplied in a solution of methanol:water:formic acid, and subsequently diluted with double
distilled water and maintained at -80 °C, and brought to room temperature for no more than 20
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minutes during use. In a study conducted by Fujisawa et al. (2008), allicin demonstrated
biological and chemical half-lives of 6 and 11 days, respectively; however, the duration of their
study was conducted at room temperature (20-22 °C). In a separate study observing the longterm stability of garlic products, it was determined that there was no loss of any thiosulfinate
between 3 and 24 months upon storage at -80 °C. While we cannot definitively conclude that
there was no breakdown of our allicin during thawing periods at room temperature without the
use of mass spectrometry, we are confident that our compound maintained its stability and purity
throughout the duration of our research.

Lastly, given that allicin was supplied via a stock vehicle containing both methanol and formic
acid, it is prudent to acknowledge potential confounds in our data. While methanol is known for
systemic cytotoxicity, Oyama et al. (2002) demonstrated no statistically-significant differences in
cell viability up to concentrations of 3 mM. Given that our allicin vehicle concentration was
diluted from 61.6256 mM to 5 μM (a >1000X dilution), we suspect that the effects of methanol
had a negligible impact on our results. While formic acid, an inhibitor of cytochrome oxidase,
has been described as a hypoxia- and acidosis-inducing agent (Liesivuori, 2014), our study
revealed no demonstrable data that NO production, eNOSSer1177 phosphorylation, or normal cell
morphology was affected. These data stem from our results that allicin did not stimulate NO
production nor eNOSSer1177 phosphorylation in HCAEC, though did stimulate both effects in
DHCAEC-I. Further, both cell types maintained similar morphologies pre- and post-allicin
treatment. We, therefore, suspect that neither methanol nor formic acid had any statistically-
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significant confounding effects in our study, though future experiments with a vehicle control at
similar concentrations are needed to confirm these assumptions.

Collectively, our data provide evidence supporting the hypothesis that allicin stimulates eNOSdependent NO production via the stimulation of PI3K, however further in vitro studies are
needed to fully elucidate the mechanism and in vivo studies to support its use in the prevention of
T1DM-induced CVD. Our data illustrate that allicin increases H2S production, NO production,
and the phosphorylation of eNOSSer1177, and that the latter two are dependent on PI3K in
DHCAEC-I. However, allicin has no apparent effect on HCAEC aside from H2S production.
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SUMMARY
Our data strongly support the hypothesis that allicin can alleviate T1DM-induced reductions and
bioavailability of NO in human coronary artery endothelial cells. Our findings provide
supporting evidence that allicin 1) increases H2S production in HCAEC and DHCAEC-I; 2)
increases NO production in DHCAEC-I only; and 3) increases eNOSSer1177 phosphorylation in
DHCAEC-I only. These findings provide a preliminary understanding of the allicin’s
vasodilatory mechanism and a new direction in drug development for the treatment of CVD in
T1DM.
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